Zinc(II) Complexes - A New Group of Non-Mutagenic Herpes Simplex Virus Inhibitors by Pesheva, Margarita & Varadinova, Tatiana
Metal-BasedDrugs Vol. 7, No.3, 2000
ZINC (II) COMPLEXES ANEWGROUP OF NON-MUTAGENIC
HERPES SIMPLEX VIRUS INHIBITORS
Margarita Pesheva and Tatiana Varadinova.2
Department of Genetics 2 Laboratory of Virology; Faettlty of Biology; Sofia University;
1421 Sofia, Bulgaria. tvar@ns.biofac.unisofia.bg, Fax: + 359 2656 641
Abstract
Former studies showed that complexes of Zn(II) with pieolinie and with aspartie acids,
Zn(pie)2 and Zn(asp)2, are able to inhibit HSV infection in cultured cells by affecting key steps
of virus replication. As these complexes are candidates for a novel class anti-HSVdrugs,
further studies on their mutagenieity are of particular interest. In the present paper we present
data showing that Zn(pie)2 and Zn(asp)2 do not express mutagenic effect in both prokaryotie
(Salmonella typhimurlum) and eukaryotie (Saccharomices cerevisiae) test systems.
Introduction
Systematic studies of the relationship between chemical structure and efficacy or toxicity of
metal compounds began around 1931 when Collier and Kraus described the first systematic
studies of tumour-inhibiting metal complexes (1). Among metal compounds used in medicine
are zinc ones: ZnSO4 is reeommeneed for the treatment of conjunctivitis, laryngitis and
vagynitis, while ZnO is used for topical application against skin diseases. The anti-herpes virus
activity of zinc was firstly described by Falke in 1967 (2). Added to Herpes simplex virus
(HSV) infected cells, ZnSO4 acts in dose-dependent manner, i. e. concentrations of 0.05
0.1mM inhibit the synthesis of HSV proteins (3, 4); 0.2mM suppressed the activity of viral
DNA polymerase (3-6), while 15mM decrease the infectious activity of extraeellular virions
interacting with viral glyeoproteins gB and gD (7). Previously reported studies have shown
that complexes of Zn(II) with picolinie and aspartie acids are able to inhibit HSV infection in
cultured cells by affecting key steps of virus replication (8, 9). As these complexes are
candidates for a novel class anti-HSV drugs, further studies on their mutagenieity are of
particular interest. In the present paper we present data showing that both Zn(pie)2 and
Zn(asp)2 do not express any mutagenie effect.
Materials and Methods
The mutagenicity of Zn(asp)2 and Zn(pic)2, in concentrations of 100, 10 and ltM, previously
recognised as non-toxic f6r cultured cells (8, 9) was evaluated. The mutagenicity of zinc
compounds was evaluated on both prokaryotic Salmonella typhimurium, strains TA100 and
TA98 (10), and eukaryotic Saccharomices cerevisiae, strains PV2 and PV3 (11) systems. S.
typhimurium strains are auxotrophic by his and are characterised by gene mutations in hisG
and hisD loci respectively (10). The genotype of the S. cerevisiae strain PV2 is:
MATa hi$7-1 ade-47,5 1y2-67 can1 R,4D1
MATa his7-1 ade-475 1ys2-68 CAN1 radl-5
The normal allele of the RAD1 gene is required for excision repair. The PV3 strain has the
same genotype but is homozygous at the radl-5 allele (11). As a result of a mutation in radl-
5 the susceptibility of the PV3 strain to different agents, here including metal compounds, is
increased. The prototrophics obtained by reversion of the ochre mutations of his7-1 and
mitotic gene conversion ]n the lys2 genes were considered. The reversion by his was evaluated
using selective medium without his. The mitotic gene conversion was evaluated using selective
medium without lys (11). The reversion induced by Zn-compounds in S. typhimurium was
evaluated without a microsomal fraction $9 (10). Analyses of the induction 0i" the reversions
and mitotic gene conversion, as well as of the lethal effect of Zn(asp)2 and Zn(pic)2 in S.
cerevisiae were evaluated by Inge-Vechtomov et al. (11). Cells from the logarithmic phase of
growth cultured at 30C in a liquid YPD (DIFCO) medium with aeration were pelted, washed
twice in potassium phosphate buf(er (PPB) (pH 7.4) and resuspended in the same buffer until
the final concentration of 10"-10 cells/ml. Mixtures of 98 % cell suspension and 2% of Zn-
compound in different concentrations were incubated for 4h at 30C. Compounds were
removed by washing in an ice-cold buffer, pelting and resuspending cells in lml PPB. The
induction of reversions, as well as the mitotic gene conversion were studied on the 5th day
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after culturing cells at 30C onto two selective solid media. The viability was evaluated on the
3rd day after culturing at 30C onto YPD solid medium. Each experiment was in triplicate and
the average number of colonies was statistically evaluated (11, I2). A frequency greeter than
at least 2-fold over the control background was judged as a significant (13).
Results and Discussion
The his D 305 2 mutation in the S. typhimurium strain TA98 is localised in
his D gene encoding histidine dehydrogenase. This is why TA98 is useful for detecting various
frameshift mutagens. The mutation in the other strain, TA100, localised in the his G-46 gene
encoding the enzyme participated in the biosynthesis of histidine and is suitable for detecting
mutagens causing G C base pair substitutions (14).
The fact that under the action of 1001.tM and 10 l.tM of Zn(asp)2 and Zn(pic)_ no significant
differences in the number of TA98 and TA100 revertants are obtained undoubtedly show that
the zinc complexes do not induce any frameshift mutation in the TA98 strain, nor base-pair
substitution in the strain TA100. This is why the effect of ll.tM was not tested (table 1).
Table 1. Induction of reversions in prokaryotic s.
Concentration, in tM
Zn(asp)2
Control
Zn(pic)_
100
lo
100
10
Control
as an average Nr of colonies
vphimurium test system
Nr of revertants*:
strain TA98
49
55
54
54
54
55
strain TA100
175
i78
183
168"
155
t84
As far as eukaryotic S. cerevisiae cells are concerned, Zn(asp)2 significantly reduced the
viability of cells from both tested strains (table 2). No dose-dependent effect nor strain
specific response were found.
In contrast, the response of S. cerevisiae cells against Zn(pic) was strain specific (table 3).
Thus, the survival rate of PV2 cells was progressively reduced when the concentrations of the
complex decreased. This is well manifested by the fact that ll.tM of Zn(pic)2 significantly
reduced cell viability as compared to the control. In the concentration range 100-1tM, this
complex significantly suppressed the surveillance of PV3 cells as well. The effect was dose-
independent and the surviving rate was similar to that obtained after influence PV3 strain with
Zn(asp).
Table 2. Zn(asp)z induced reversion and
Strain Concentration, in Niu
Control
PV3
cOntrol
total Nr
100
10
100
0
44’2
497
458
732
444
480
390
ene conversion in S. cerevisiae strains PV2 and PV3.
Viability, in % Nr of prototrophic mutants
01er
tyoe*
His x 1 Lys x 10
60.4+2.3 2.7+0.08 1.7+0.16
67.9+2. ,7+/-0.08 3.3+/-0.14
62.6+2.3 2.3+0.i6 4.0+0.16
1000 i3+/-0.06 2.3+/-0.16
62.4+2.3 3.0+/-0.13 5.7+/-0.16
67.4+/-2. 43+/-0.0’8 9.3+/-0.32’
54.8+2.5 4,7+/-’ 08 10.7+/-0.18
712 100 0 2.7+0.08’ 4.7:k0.12
f viable cells; * as an average Nr of colonies; p < 0.05
In our eukaryotic experimental system, the mutagenic effect of a particular compound is
manifested by the appearance of prototrophic colonies, as a result of reversion of ohre
mutation in the his7-1 locus. According to Parry (13) the tested compound is recognised as a
mutagen when the number, of prototrophic colonies is at least two times higher than that in
the control. As shown in tables 2 and 3, the number of prototrophic colonies induced by
Zn(asp): and Zn(pic)_ is not significantly different as compared to the control and show that
both zinc complexes did not induce reversion in his7-1 locus.
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Zn(pie)2 did not induce any gene conversion in the lys2 gene of both PV2 and PV3 strains as
well. However, the number of prototrophie PV3 but not of PV2 colonies after action with
l l.tM Zn(asp)2 was 2.3 times higher than that in the control.
Table 3. Zn(pic) induced reversion and ene conversion in S. cerevisiae strains PV2 and PV3
Strain Coneentrati0n, in Ni" Viability, in % Nr of prototrophie mutants
M per type*
PV2
Control
PV3
Control
total Nr c
100 393 99.5)0.4
i0 324 82.0)2.1
281 71.1)2.7
395 10.0
100 531 66.4 )2.0
10" 572 71.5)1.9
474 59,2)2.2
80’0 100.0 2. O0.06
f viable cells; * as an average Nr of colonies; p < 0.05
His x i0
1.7)0.08. 3.060.16
2.30.1
1.3)0.08
4.3!)0.14
4.7()0 8
5’.3.)0.2
Lys.x 10
2.7.00.09
3.080.16 33 0.16
2.30.08 6.7.0.15
8.3Q0.18
9 7Q0,35
5.300 16
To summarise, the data show that the mutagenicity of a particular zinc complex depends
i) on the specific characteristics of the complex itself: Zn(pic)_ is a mutagen neither for
prokaryotic, nor for eukaryotic test systems, while Zn(asp)_ expressed a weak mutagenic
effect in eukaotic S. cerevisiae strain PV3 only.
ii) on the specificity of the test system. Zn(asp)2 is not a mutagen for S. typhimurium strains,
nor for S. cerevisiae strain PV2. The sensitivity of the S. cerevisiae strain PV3 to IM
Zn(asp)2 _is.manifested by a weak mutagenic effect, obviously due to the disturbed reparation
system of this strain.
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